Breaking News

AnGes, Mitsubishi Tanabe in Marketing Pact

October 26, 2012

AnGes gains rights to Collategene in the U.S.

AnGes MG has entered into a definitive agreement with Mitsubishi Tanabe Pharma Corp. for the exclusive marketing rights to Collategene (DNA Plasmid with HGF gene), a treatment for Peripheral Arterial Disease (PAD) in the U.S. AnGes will receive upfront payments, performance based milestone payments and sales-based milestones after the product launch.
 
Ei Yamada, president and chief executive officer of AnGes, said, "We are pleased that we can commence the Phase III global trial of Collategene as a treatment for Critical Limb Ischemia (CLI), an intractable disease. The U.S. takes active measures toward promoting new drug development, and the country has the largest market for the drug for CLI, which cannot be treated with existing treatments. We estimate that the potential market for the drug is about $5 billion. AnGes aims to obtain the marketing approval in the U.S. at an early date by promptly advancing the development. We will definitely achieve this by establishing a cooperative structure with MTPC, a strong partner we long-sought."
blog comments powered by Disqus
  • FDA & Drug Development

    FDA & Drug Development

    Rachelle Du2019Souza, Regulatory Heights Inc.||September 8, 2016
    You must perform the necessary due diligence to stay on top of regulatory developments

  • The Role of Alliances in Modern Drug Development

    The Role of Alliances in Modern Drug Development

    Dr. Claire Madden-Smith, Senior Vice President, Juniper Pharma Services||September 8, 2016
    Combining expertise to get drug candidates through development

  • Successful Method Transfer of Solid Oral Dosage

    Successful Method Transfer of Solid Oral Dosage

    John Frankonis, Ropack Pharma Solutions||June 2, 2016
    The three steps outlined will help guide the process of completing a successful analytical method transfer